CTOR Insider Trading
Citius Oncology, Inc. (CTOR) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry, with a market capitalization near $82.7M, listed on NASDAQ, employing roughly 285 people, carrying a beta of 3.58 to the broader market. Citius Oncology, Inc. Led by Leonard L. Mazur, public since 2022-12-08.
In the last 12 months, Citius Oncology, Inc. insiders made 0 buy transactions and 0 sale transactions.
| Date | Name | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 23, 2025 | HOLUBIAK MYRON Z | A-Award | 850,000 | $0.00 | $0 |
| Sep 23, 2025 | HOLUBIAK MYRON Z | A-Award | 100,000 | $0.00 | $0 |
| Sep 23, 2025 | Smith Robert Joseph | A-Award | 300,000 | $0.00 | $0 |
| Sep 23, 2025 | Mazur Leonard L | A-Award | 1,700,000 | $0.00 | $0 |
| Sep 23, 2025 | Webb Carol | A-Award | 300,000 | $0.00 | $0 |
| Sep 23, 2025 | Czuczman Myron | A-Award | 825,000 | $0.00 | $0 |
| Sep 23, 2025 | MCGRATH DENNIS M | A-Award | 300,000 | $0.00 | $0 |
| Sep 23, 2025 | Bartushak Jaime | A-Award | 825,000 | $0.00 | $0 |
| Sep 23, 2025 | Mayersohn Joel David | A-Award | 300,000 | $0.00 | $0 |
| Sep 23, 2025 | Dutia Suren G | A-Award | 300,000 | $0.00 | $0 |
How to Read CTOR Insider Activity
Net insider activity is balanced over the trailing twelve months: 0 buys against 0 sales. Balanced activity typically reflects routine compensation-related vesting and tax-driven liquidity rather than directional information signals. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.
Learn how insider trading is reported and how to read the data →
Frequently asked CTOR insider trading questions
- How active are CTOR insiders right now?
- Over the trailing twelve months, Citius Oncology, Inc. (CTOR) insiders made 0 buy transactions and 0 sale transactions. Net insider activity over the trailing twelve months is balanced (0 buys, 0 sales). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
- What counts as an insider transaction?
- Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
- Are CTOR insider buys a bullish signal?
- Insider open-market purchases (Type P) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
- How do CTOR insider transactions affect options pricing?
- Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.